Back to Search Start Over

The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial.

Authors :
Bundgaard JS
Thune JJ
Nielsen JC
Videbæk R
Haarbo J
Bruun NE
Videbæk L
Aagaard D
Korup E
Jensen G
Hildebrandt P
Steffensen FH
Eiskjær H
Brandes A
Thøgersen AM
Melchior TM
Pedersen OD
Gustafsson F
Egstrup K
Hassager C
Svendsen JH
Høfsten DE
Torp-Pedersen C
Pedersen SS
Pehrson S
Køber L
Mogensen UM
Source :
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology [Europace] 2019 Jun 01; Vol. 21 (6), pp. 900-908.
Publication Year :
2019

Abstract

Aim: The Danish Study to Assess the Efficacy of Implantable Cardioverter-Defibrillators (ICD) in Patients with Non-ischaemic Systolic Heart Failure (HF) on Mortality (DANISH) found no overall effect on all-cause mortality. The effect of ICD implantation on health-related quality of life (HRQoL) remains to be established as previous trials have demonstrated conflicting results. We investigated the impact of ICD implantation on HRQoL in patients with non-ischaemic systolic HF, a prespecified secondary endpoint in DANISH.<br />Methods and Results: In DANISH, a total of 1116 patients with non-ischaemic systolic HF were randomly assigned (1:1) to ICD implantation or usual clinical care (control). Patients completed disease-specific HRQoL as assessed by Minnesota Living with Heart Failure Questionnaire (MLHFQ; 0-105, high indicating worse). Changes in HRQoL 8 months after randomization were assessed with a mixed-effects model. At randomization, MLHFQ was completed by 935 (84%) patients (n = 472 in the ICD group and n = 463 in the control group) and was reassessed in 274 (58%) and 292 (63%) patients, respectively after 8 months for the primary analysis. Patients in the ICD group vs. the control group had similar improvements in MLHFQ after 8 months [least square mean -7.0 vs. -4.2 (P = 0.13)]. A clinically relevant improvement (decrease ≥5) in the MLHFQ overall score at 8 months was observed in 151 patients in the ICD group and 148 patients in the control group [55% vs. 51%, respectively (P = 0.25)].<br />Conclusion: Implantable cardioverter-defibrillator implantation in patients with non-ischaemic systolic HF did not significantly alter HRQoL compared with patients randomized to usual clinical care.<br /> (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1532-2092
Volume :
21
Issue :
6
Database :
MEDLINE
Journal :
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
Publication Type :
Academic Journal
Accession number :
30796456
Full Text :
https://doi.org/10.1093/europace/euz018